Related by context. All words. (Click for frequent words.) 74 Chronic Lymphocytic Leukemia CLL 73 relapsing remitting MS RRMS 72 recurrent glioblastoma multiforme 71 leukemia AML 71 metastatic malignant 70 Chronic lymphocytic leukemia 70 recurrent NSCLC 70 systemic anaplastic large 70 refractory chronic lymphocytic 70 Waldenstrom macroglobulinemia 69 essential thrombocythemia ET 69 metastatic pancreatic 69 antibody MAb 69 Temsirolimus 69 refractory acute myeloid 69 gefitinib Iressa 69 thalidomide Thalomid 69 Cloretazine 69 relapsed MM 69 lymphoid malignancies 69 Hepatocellular Carcinoma HCC 68 nonmetastatic 68 CYT# potent vascular disrupting 68 CTAP# Capsules 68 myelodysplastic myeloproliferative diseases 68 leukemia ALL 68 LymphoStat B belimumab 68 Advanced Renal Cell 68 metastatic bladder 68 papillary renal cell carcinoma 68 Glioblastoma Multiforme 68 evaluating tivozanib 68 Severe Sepsis 68 demonstrated antitumor activity 68 pediatric acute lymphoblastic 68 LHRH receptor positive 68 STRIDE PD 68 Philadelphia Chromosome Positive 68 hypereosinophilic syndrome 68 Myelodysplastic Syndrome 68 Cutaneous T 68 Relapsed Refractory 68 IL# PE#QQR 67 Myelofibrosis 67 fallopian tube carcinoma 67 cutaneous T 67 dasatinib Sprycel 67 recurrent metastatic 67 metastatic colorectal 67 relapsing multiple sclerosis 67 Campath alemtuzumab 67 Atypical Hemolytic Uremic Syndrome 67 complement inhibitor eculizumab 67 Nilotinib 67 sorafenib Nexavar 67 mycosis fungoides 67 pancreatic adenocarcinoma 67 Myelodysplastic Syndrome MDS 67 AA Amyloidosis 67 Brentuximab Vedotin SGN 67 psoriatic arthritis PsA 67 Hormone Refractory Prostate Cancer 67 operable breast cancer 67 cell lymphoma CTCL 67 metastatic gastric 67 systemic lupus erythematosus SLE 67 anthracyclines taxanes 67 Systemic Sclerosis 67 Patients Treated With 67 selective modulator 67 depsipeptide 67 Mantle Cell Lymphoma 67 relapsed mantle 67 acute myeloid 67 Acute myeloid leukemia 67 Lymphocytic 67 stage IIIb IV 67 Diffuse Large B 67 forodesine 67 cancer mCRC 66 kidney urologic 66 YONDELIS 66 sunitinib malate 66 Ph + acute lymphoblastic 66 generation purine nucleoside 66 Non Hodgkin 66 acute leukemias 66 indolent follicular non 66 Rituxan rituximab 66 myeloid metaplasia 66 taxane chemotherapy 66 leukemia CLL 66 Chronic Lymphocytic Leukemia 66 refractory indolent non 66 metastatic renal 66 advanced hepatocellular carcinoma 66 Amrubicin 66 Randomized Phase 66 MGd 66 Peginterferon alfa 2b 66 familial amyloidotic polyneuropathy FAP 66 Fludara ® 66 polycythemia vera PV 66 previously untreated follicular 66 Personalized Immunotherapy 66 Gleevec imatinib mesylate 66 Bezielle 66 chronic thromboembolic pulmonary 66 metastatic renal cell 66 smoldering multiple myeloma 66 HER2 amplified 66 chronic myeloid 66 novel VDA molecule 66 ELACYT 66 Adjuvant chemotherapy 66 multiple myeloma MM 66 Sipuleucel T 66 Acute Myeloid Leukaemia AML 66 docetaxel Taxotere ® 66 Anthracycline 66 Fludarabine 66 advanced metastatic renal 66 relapsed leukemia 66 Acute myeloid leukemia AML 66 advanced metastatic prostate 66 receptor tyrosine kinase inhibitor 66 Leukemias 66 follicular Non Hodgkin 66 ZACTIMA 66 erlotinib Tarceva ® 66 resistant hormone refractory 66 hepatocellular carcinoma HCC 66 systemic lupus erythematosus 66 vinca alkaloid 66 smoldering myeloma 66 PNP inhibitor 66 transplantation HCT 66 pediatric malignancies 66 standard chemotherapy regimen 66 homozygous familial hypercholesterolemia 66 Adenomas 66 BCR ABL inhibitor 66 systemic juvenile idiopathic 66 chronic eosinophilic leukemia 66 malignant pleural mesothelioma 66 chronic lymphocytic leukemia CLL 66 androgen receptor antagonist 65 diagnosed Ph + 65 biliary tract cancer 65 lintuzumab SGN 65 TTR amyloidosis 65 Multiple Myeloma MM 65 Doxil ® 65 diffuse gastric 65 Decitabine 65 myelodysplastic syndrome MDS 65 dasatinib Sprycel ® 65 opioid induced constipation OIC 65 chronic granulomatous disease 65 epithelial tumors 65 castrate resistant prostate cancer 65 hyperphenylalaninemia HPA due 65 alkylating agent 65 aplastic anemia AA 65 non metastatic osteosarcoma 65 Vidaza azacitidine 65 lupus nephritis 65 CALGB # [002] 65 allogeneic HSCT 65 mTOR mammalian target 65 minimally symptomatic 65 colorectal liver metastases 65 thymoma 65 Bayer HealthCare Onyx Pharmaceuticals 65 haematologic 65 R lenalidomide 65 myeloproliferative diseases 65 Stage IIB 65 MELAS 65 cell acute lymphoblastic 65 myelofibrosis MF 65 R sorafenib tablets 65 Epratuzumab 65 targeted antifolate 65 Kit CD# positive 65 monoclonal antibody conjugated 65 alfa 2a 65 mertansine 65 thetreatment 65 JAK2 inhibitor 65 AML MDS 65 Follicular Lymphoma 65 Pathway Inhibitor 65 imatinib Gleevec 65 prostate adenocarcinoma 65 cetuximab Erbitux 65 FOLOTYN ® 65 sunitinib Sutent 65 gemcitabine Gemzar 65 epithelial ovarian 65 Nexavar sorafenib 65 Chronic Heart Failure 65 gastrointestinal stromal tumor GIST 65 SPRYCEL ® 65 HeFH 65 Chronic Myelogenous Leukemia 65 T1c 65 myeloproliferative neoplasms 65 Safinamide 65 MAGE A3 ASCI 65 MKC# MT 65 BR.# 65 achieved CCyR 65 Completes Patient Enrollment 65 myeloproliferative disorders 65 Romiplostim 65 Cancer Incidence Mortality 65 pain palliation 65 HCV SPRINT 65 somatostatin analogue 65 unresectable tumors 65 Velcade bortezomib 65 NMIBC 65 unresectable stage 65 HER2 positive metastatic breast 65 polycythemia vera essential thrombocythemia 65 GW# [003] 65 Meets Primary Endpoint 65 Vidaza ® 65 anthracycline taxane 65 Enzyme Replacement Therapy 65 idiopathic thrombocytopenic purpura ITP 65 brivanib 65 trial evaluating PRX# 65 transthyretin amyloidosis 65 Pegloticase 65 non nucleoside inhibitor 65 Natalizumab 65 ErbB2 positive 65 myelofibrosis polycythemia vera 65 Tyrosine Kinase Inhibitors 65 recurrent malignant glioma 65 Novel Oral 65 CIMZIA TM certolizumab pegol 65 nilotinib Tasigna 65 Alemtuzumab 65 Familial Adenomatous Polyposis 65 p# biomarker 65 Intravenous CP 65 Subtypes 65 metastatic GIST 65 Romidepsin 64 Phase #b/#a clinical 64 endometriosis ovarian cysts 64 Combination REOLYSIN R 64 Prolongs Survival 64 Chronic Myelogenous Leukemia CML 64 Granted Orphan Drug 64 adalimumab Humira 64 superficial bladder cancer 64 HER2 overexpression 64 orally inhaled migraine 64 oxaliplatin Eloxatin 64 nonsmall cell lung cancer 64 PEGylated interferon beta 1a 64 AVOREN 64 Myelodysplastic Syndromes 64 bladder carcinoma 64 Ozarelix 64 Acute Myeloid Leukemia AML 64 oral Janus kinase 64 Pralatrexate 64 Systemic lupus erythematosus SLE 64 cisplatin gemcitabine 64 metastatic hormone refractory 64 Accelerated Partial Breast Irradiation 64 Zarnestra 64 acute myelogenous leukemia AML 64 BCIRG 64 LymphoStat B TM 64 Immunotherapeutic 64 Acute Exacerbations 64 Hedgehog Pathway Inhibitor 64 gastrointestinal stromal tumor 64 Aflibercept 64 malignant neoplasm 64 vidofludimus 64 Pemetrexed 64 atypical hemolytic uremic syndrome 64 stage IIIB 64 Idiopathic Pulmonary Fibrosis IPF 64 JAK2 Inhibitor 64 histone deacetylase HDAC inhibitor 64 Janus kinase 64 cediranib 64 commercialize deforolimus 64 gemcitabine Gemzar ® 64 rheumatoid arthritis psoriatic arthritis 64 AVONEX ® 64 non squamous NSCLC 64 sorafenib tablets 64 Bronchiectasis 64 humanised monoclonal antibody 64 Malignant Melanoma 64 Chronic myeloid leukemia 64 Diabetic Macular Edema 64 paclitaxel Taxol R 64 refractory cutaneous T 64 bone metastasis 64 Folfox 64 galiximab 64 Systemic Lupus Erythematosus SLE 64 mRCC 64 CLL SLL 64 dose escalation clinical 64 invasive aspergillosis 64 heavily pretreated 64 Plicera 64 cytomegalovirus infection 64 Pharmacokinetics PK 64 Achieves Primary Endpoint 64 recurrent glioblastoma multiforme GBM 64 AEG# 64 Chronic lymphocytic leukemia CLL 64 Phase 2b Clinical Trial 64 Factor Receptor 64 relapsed GBM 64 Cimzia TM 64 alpha1 antitrypsin deficiency 64 PKC# 64 unresectable liver cancer 64 Hsp# Inhibitor 64 relapsed refractory multiple myeloma 64 EGFr expressing metastatic colorectal 64 vWD 64 5 fluorouracil leucovorin 64 de novo kidney transplant 64 Cloretazine ® 64 recurrent GBM 64 temozolomide Temodar 64 Progressive Multifocal Leukoencephalopathy 64 pancreatic islet cell 64 corticosteroid dexamethasone 64 BRIM2 64 rALLy clinical trial 64 Hematological Malignancies 64 decompensated liver disease 64 rALLy 64 acadesine 64 Presents Preclinical 64 ductal carcinomas 64 benign prostatic hypertrophy BPH 64 interferon gamma 1b 64 Evoltra ® 64 LUX Lung 64 invasive candidiasis 64 Successfully Completes Phase 64 Sprycel dasatinib 64 imatinib Gleevec ® 64 K ras mutations 64 Cloretazine R 64 Begins Dosing 64 measurable tumor regressions 64 severe hypercholesterolemia 64 Xelox 64 Renal Cell Carcinoma RCC 64 Intravenous immunoglobulin 64 small molecule Hedgehog 64 targeted radiotherapeutic 64 assessing T DM1 64 refractory metastatic 64 Bosutinib 64 phase IIb trial 64 grade cervical dysplasia 64 non Hodgkin lymphomas 64 hormone receptor negative 64 Cell Lymphoma 64 Ribavirin causes 64 chronic idiopathic thrombocytopenic purpura 64 HNSCC 64 severe neutropenia 64 evaluating picoplatin 64 erythematosus 64 haematological cancers 64 TORISEL TM 64 refractory colorectal cancer 64 Soft Tissue Sarcoma 64 Medullary thyroid cancer 64 medullary thyroid cancer 64 allogeneic hematopoietic stem cell 64 idiopathic myelofibrosis 64 Azacitidine 64 essential thrombocythemia 64 AKT inhibitor 64 severe oral mucositis 64 including eniluracil ADH 64 visceral metastases 64 aMCI precursor 64 Vectibix panitumumab 64 Phase Ib II 64 lymphoma CTCL 64 relapsed ALL 64 Surgical resection 64 Carotid Revascularization Endarterectomy vs. 64 Torisel temsirolimus 64 acute lymphoblastic 64 cetuximab Erbitux R 64 Yondelis ® 64 BCG refractory 64 recurrent epithelial ovarian 64 Sezary syndrome 64 Lenocta 64 chronic HBV 64 carcinoid tumors 64 metastatic carcinoma 64 Elagolix 64 refractory CTCL 64 pelvic malignancies 64 Glioblastoma Multiforme GBM 64 Hepatocellular Carcinoma 64 ExTRACT TIMI 64 sodium thiosulfate STS 64 Myelodysplastic syndromes 64 leukemia multiple myeloma 64 HDAC Inhibitor 64 APPRAISE 64 Tramiprosate ALZHEMED TM 64 Gleevec resistant 64 metastatic castration resistant 64 Enzastaurin 64 hepatorenal syndrome 64 Voreloxin 64 SHPT 64 Tasimelteon 64 INSPIRE Trial Phase III 64 adult chronic ITP 64 verteporfin 64 Aplidin 64 vapreotide acetate 64 pan HDAC inhibitor 64 Tyrosine Kinase Inhibitor 64 evaluating mipomersen 63 indolent NHL 63 recurrent ovarian cancer 63 huN# DM1 63 SJIA 63 acute GvHD 63 Lupus Nephritis 63 OMP #R# 63 TNF Tumor Necrosis Factor 63 KRAS mutations occur 63 panitumumab Vectibix 63 Adjuvant Treatment 63 colorectal carcinoma 63 non splenectomized 63 underwent resection 63 Genasense ® 63 toenail onychomycosis 63 hormone refractory metastatic prostate 63 myeloproliferative 63 rufinamide 63 Quinamed 63 elacytarabine 63 RANK Ligand inhibitor 63 HQK 63 ixabepilone 63 Improves Outcomes 63 Degarelix 63 pT2 63 gastrointestinal stromal tumors GISTs 63 dirucotide MBP# 63 haematologic malignancies 63 oral ghrelin agonist 63 follicular lymphoma FL 63 underwent surgical resection 63 metastatic kidney 63 investigational humanized monoclonal antibody 63 Stage IIIb 63 Triapine 63 leukemia lymphoma multiple myeloma 63 Lenalidomide 63 Bucindolol 63 Prednisone Against Refractory 63 bevacizumab Avastin ® 63 undergoing hematopoietic stem 63 small lymphocytic lymphoma 63 histologically confirmed 63 Arimidex anastrozole 63 Friedreich Ataxia FRDA 63 Albuferon TM 63 lupus erythematosus 63 non resectable 63 phase III isavuconazole 63 Arzerra ofatumumab 63 ® lenalidomide 63 Hydroxyurea 63 lexidronam injection 63 IBS C 63 radiation sensitizer 63 metastatic colorectal carcinoma 63 ipsilateral breast 63 PEGylated Fab fragment 63 metastatic renal cell carcinoma 63 Bevacizumab Avastin 63 chronic rheumatic 63 lymphomas leukemias 63 IMiDs ® compound 63 Initiates Phase III 63 Denufosol 63 lumiliximab 63 IV melanoma 63 IV NSCLC 63 selective phosphodiesterase 63 Papillary 63 nucleotide analog 63 Preclinical Models 63 acetonide FA 63 ovarian endometrial 63 dacarbazine DTIC 63 Muraglitazar 63 cytoreduction 63 Relapsed Multiple Myeloma 63 relapsed refractory 63 NSABP B 63 stage IIIb 63 MYLOTARG 63 trastuzumab DM1 T DM1 63 cisplatin resistant 63 leiomyomas 63 PI3K/Akt pathway inhibitor 63 idiopathic thrombocytopenic purpura 63 microsphere therapy 63 colorectal adenoma 63 Genasense ® oblimersen 63 Initiates Enrollment 63 Myelodysplastic syndromes MDS 63 Ischemic 63 lenalidomide Revlimid R 63 cell lymphoma ALCL 63 PEGINTRON TM 63 Paraplatin ® 63 agonistic human 63 rituximab refractory follicular 63 Carcinoid tumors 63 Gleevec imatinib 63 TEMODAL 63 IMA# 63 resectable pancreatic cancer 63 recurrent glioblastoma 63 Omacetaxine 63 beta 1a 63 antiretroviral naïve 63 anthracycline containing 63 pancreatic lung 63 Randomized Study 63 registrational trial 63 hepatocellular carcinomas 63 vinca alkaloids 63 Presents Positive 63 bronchogenic carcinoma 63 basal cell carcinoma BCC 63 Randomized Phase II 63 chronic ITP patients 63 rheumatoid arthritis inflammatory bowel 63 Neulasta R 63 orally administered inhibitor 63 paraganglioma 63 Uvidem 63 skeletal metastases 63 alkylating 63 Motesanib 63 rituximab refractory 63 Squamous 63 pouchitis 63 erlotinib Tarceva 63 TREANDA 63 cyclophosphamide methotrexate 63 Talabostat 63 Idiopathic Pulmonary Fibrosis 63 melphalan prednisone 63 Anaplastic 63 eosinophilic asthma 63 Genentech Rituxan 63 number NCT# ClinicalTrials.gov 63 constipation OIC 63 Parathyroid Hormone 63 metachronous 63 patientswith 63 anastrazole 63 MEK Inhibitor 63 Chronic Myeloid Leukemia 63 Crohn disease CD 63 histologic subtype 63 Syndrome LEMS 63 Antitumor Activity 63 anti CD3 antibody 63 secondary hyperparathyroidism 63 Initiates Phase II 63 prostate cancer HRPC 63 R roscovitine 63 Morquio 63 Tarceva TM 63 arthritis PsA 63 FUSILEV enhances 63 neuroendocrine cancers 63 AVASTIN 63 chemo immunotherapy 63 pediatric Crohn disease 63 primary hyperparathyroidism 63 keloid scarring 63 paclitaxel Taxol 63 lymphoid tumors 63 demethylating agent 63 schizophrenia CIAS 63 axitinib 63 investigational monoclonal antibody 63 peptidic compound 63 hepatocellular carcinoma liver 63 adrenocortical cancer 63 Pulmonary Arterial Hypertension PAH 63 hematological diseases 63 Antiviral Therapy 63 ALN TTR 63 pulmonary metastases 63 vemurafenib 63 homozygous FH 63 lymphoproliferative disorders 63 investigational immunotherapy 63 chemoresistant 63 Camptosar ® irinotecan 63 TACI Ig 63 ZOLINZA 63 ductal adenocarcinoma 63 childhood acute lymphoblastic 63 Advanced Melanoma 63 Panzem ® 63 diabetes mellitus DM 63 Pivotal Clinical Trial 63 PANVAC VF 63 RhuDex R 63 Dacogen injection 63 immunomodulatory therapy 63 sarcomatoid 63 Heterozygous Familial Hypercholesterolemia 63 IgG1 monoclonal antibody 63 bladder ovarian 63 huC# DM4 63 docetaxel cisplatin 63 completely resected 63 Gemzar gemcitabine 63 PDX pralatrexate 63 Arranon 63 Elotuzumab 63 multicenter phase 63 AAG geldanamycin analog 63 Panzem R 63 Vascugel 63 metastatic neuroendocrine tumors 63 Daclizumab 63 ara C 63 Neuvenge 63 alvespimycin 63 chimeric monoclonal antibody 63 XL# XL# 63 Ocrelizumab 63 Li Fraumeni Syndrome 63 registrational Phase 63 cilengitide 63 thromboembolic disease 63 Pooled Analysis 63 Revlimid lenalidomide 63 cytokine refractory 63 anticancer compound 63 Panzem NCD 63 trabectedin 63 pancreatic neuroendocrine tumors 63 Phase Ib IIa 63 humanized interleukin 6 63 Amgen Neulasta R 63 SAR# [004] 63 bortezomib Velcade 63 liposomal formulation 63 ankylosing spondylitis AS 63 ADPKD 63 luteinizing hormone releasing 63 Akt inhibitor 63 Acute Myelogenous Leukemia 63 Hodgkin lymphoma NHL 63 hepatitis C HCV 62 Menopausal hormone therapy 62 XYOTAX TM 62 Phase III randomized controlled 62 accumulate preferentially 62 lorvotuzumab mertansine 62 acute myelogenous 62 candidate CRLX# 62 multi kinase inhibitor 62 untreated metastatic pancreatic 62 severe malignant osteopetrosis 62 Hycamtin ® 62 dual endothelin receptor antagonist 62 pancreatic carcinoma 62 5 Fluorouracil 62 enzastaurin 62 subependymal giant cell 62 acute humoral rejection 62 fluoropyrimidine 62 HBeAg negative 62 cell carcinoma RCC 62 active ankylosing spondylitis 62 Diabetic Macular Edema DME 62 induced macular edema 62 mitoxantrone plus 62 MALT lymphoma 62 Tanespimycin 62 Clinical Trial Results 62 abacavir Ziagen 62 HBeAg positive patients 62 immune dysregulation 62 Receives Orphan Drug 62 autoantibody positive 62 colorectal cancer CRC 62 evaluating T DM1 62 hematological cancers notably 62 BRAF inhibitor 62 leukemia CML 62 resistant ovarian cancer 62 deletion 5q 62 refractory chronic myeloid 62 metastatic malignant melanoma 62 Etanercept 62 gastric carcinoma 62 paroxysmal nocturnal hemoglobinuria PNH 62 Curaxin CBLC# 62 virus HCV protease inhibitor 62 Lennox Gastaut Syndrome 62 CAMMS# 62 Laquinimod 62 PAOD 62 Bazedoxifene 62 Vicriviroc 62 differentiated thyroid 62 treat chronic sinusitis 62 acyclovir Lauriad R 62 midstage clinical 62 Vascular Disrupting Agent 62 Initiates Clinical Trial 62 MyVax R 62 Antigen Specific 62 ALK inhibitor 62 TTF Therapy 62 Vandetanib 62 Pivotal Phase III 62 R bendamustine hydrochloride 62 proteasome inhibitor 62 Juvenile Idiopathic Arthritis 62 investigational compounds 62 interstitial cystitis IC 62 substantially excreted 62 NSCLC tumors 62 Endometrial 62 lung pancreatic 62 satraplatin Phase 62 Angiotensin Converting Enzyme 62 plus DOXIL 62 Shows Efficacy 62 RECORD1 62 SNT-MC#/idebenone 62 gastric adenocarcinoma 62 hoFH 62 pertuzumab 62 untreated metastatic melanoma 62 gastrointestinal stromal tumors 62 oral Hycamtin 62 neratinib 62 OMNARIS HFA 62 nephropathic cystinosis 62 phase IIb clinical 62 PD LID 62 FOLFOX6 62 diarrhea predominant irritable 62 treatment naive genotype 62 irreversible inhibitor 62 BCG refractory carcinoma 62 Lung transplantation 62 Receives Orphan Drug Designation 62 Idiopathic pulmonary fibrosis 62 invasive lobular carcinoma 62 GVAX ® 62 REMINYL ® 62 Triapine R 62 Cotara ® 62 Octreolin 62 relapsed ovarian cancer 62 Irinotecan 62 Relapsing Remitting Multiple Sclerosis 62 Troxatyl 62 medically inoperable 62 terlipressin 62 diagnostic biomarker 62 developing Bicifadine serotonin 62 etanercept Enbrel 62 Deforolimus 62 ANCA associated 62 ovarian carcinoma 62 Golimumab 62 lymphocytic leukemia 62 novel therapeutic antibodies 62 untreated de novo 62 peritoneal carcinomatosis 62 Thalomid ® 62 INCB# [001] 62 refractory ovarian cancer 62 Gemzar ® 62 Temodar ® 62 fallopian tube cancers 62 Oral Fingolimod 62 prostate cancer PCa 62 myelodysplasia 62 nucleotide analogue 62 Cell Lymphoma CTCL 62 Xanafide 62 CHOP chemotherapy 62 PEGylated anti 62 tyrosine kinase inhibitor TKI 62 Ceflatonin R 62 histone deacetylase inhibitor 62 Diabetic nephropathy 62 antiangiogenic agent 62 metastatic ovarian cancer 62 squamous cell carcinoma SCC 62 docetaxel Taxotere R 62 Pegylated Interferon 62 Investigational Compound 62 cinacalcet 62 Stereotactic Body Radiation Therapy 62 follicular thyroid cancer 62 Acute Heart Failure 62 dimensional conformal radiation 62 SNT MC# 62 evaluating satraplatin 62 chronic GVHD 62 hematological malignancy 62 paclitaxel Taxol ® 62 genitourinary cancers 62 evaluating Xcytrin 62 LungAlert TM 62 Epidermal Growth Factor Receptor 62 sodium glucose cotransporter 62 Epigenomics proprietary 62 selective kinase inhibitor 62 EGFR expressing 62 brain metastases originating 62 metastatic lung cancer 62 Non Alcoholic Steatohepatitis 62 riociguat 62 microtubule inhibitor 62 Neulasta ® 62 OncoVex 62 recurrent ovarian 62 Efficacy Results 62 KRN# 62 LHRH antagonists 62 treat benign prostatic 62 estramustine 62 PCNSL 62 Metastatic Melanoma 62 Kaposi sarcoma KS 62 Metastatic Colorectal Cancer 62 metaglidasen 62 RezularTM 62 cyclophosphamide FC 62 sJIA 62 LHON 62 untreated multiple myeloma 62 herpes zoster shingles 62 malignant lymphomas 62 hepatocellular cancer 62 p# MAP kinase inhibitor 62 overactive bladder syndrome 62 precursor acute lymphoblastic 62 Naive Patients 62 fosbretabulin 62 Castration Resistant Prostate Cancer 62 visilizumab 62 Pegylated Liposomal Doxorubicin 62 HER2 positive cancers 62 Protease Inhibitor 62 Xyfid TM 62 BRCA deficient 62 Sanofi Aventis Taxotere 62 systemic ALCL 62 Factor VIIa 62 elotuzumab 62 Newly Diagnosed Multiple Myeloma 62 pegylated liposomal doxorubicin 62 bendamustine 62 cytogenic 62 PROSTVAC VF 62 renal cell carcinomas 62 prospectively enrolled 62 progressive neurodegenerative disorder 62 prostate cancer CaP 62 Intervention Effectiveness 62 Tesmilifene 62 Taxotere chemotherapy 62 SinuNase ™ 62 endocrine therapies 62 Panzem R NCD 62 Demonstrates Sustained 62 oligodendrogliomas 62 trastuzumab Herceptin ® 62 mGluR2 NAM 62 Dapagliflozin 62 Alequel 62 Fabry Disease 62 Myelodysplastic syndrome 62 angiogenesis inhibitor 62 Ibritumomab Tiuxetan 62 Camptosar ® 62 FLT3 mutations 62 Renal Cell Carcinoma 62 VNP#M 62 ALN PCS 62 denileukin diftitox 62 ThermoDox R 62 Pivotal Trial 62 aurora kinase 62 evaluating REVLIMID 62 Tofacitinib 62 steroid refractory GvHD 62 transthyretin TTR mediated amyloidosis 62 immune thrombocytopenic purpura 62 pancreatic NET 62 bosutinib 62 pemphigus vulgaris 62 EndoTAGTM 1 62 patients receiving myelosuppressive 62 Gleevec Glivec 62 tumors GIST 62 chronic myelogenous leukemia CML 62 targeting miR 62 SinuNase TM 62 Cardiotoxicity 62 Chronic Hepatitis C 62 Virologic 62 immunomodulatory agents 62 YONDELIS R 62 small molecule tyrosine 62 HCV NS5B polymerase 62 mGluR2 positive 62 Cell Non Hodgkin 62 autologous transplants 62 deep venous thromboses 62 Teriflunomide 62 albiglutide 62 investigational oral inhibitor 62 autologous cellular immunotherapy 62 paclitaxel poliglumex 62 nucleoside analog 62 gastrointestinal stromal 62 either acutely decompensated 62 Patients Receiving 62 efalizumab 62 oral prodrug 62 temozolomide TMZ 62 Antisoma AS# 62 psoriasis Crohn disease 62 concurrent chemoradiation 62 Diabetic Neuropathy 62 demethylation agents 62 AGILECT R 62 TRIST study 62 Gynecologic Oncology Group 62 Major Depressive Disorder MDD 62 Cetrorelix 62 relapsing remitting multiple sclerosis 62 precancerous condition 62 hormone refractory 62 5 FU leucovorin 62 Annamycin 62 biologic DMARD 62 novel emulsion formulation 62 EGFR expressing mCRC 62 Picoplatin Efficacy After 62 diagnosed glioblastoma 62 agalsidase alfa 62 RAPTIVA 62 BRAF V#E 62 Graft Versus Host 62 prostate carcinomas 62 urothelial carcinoma 61 castrate resistant 61 de novo AML 61 Intravitreal 61 malignant ascites 61 ALN VSP Phase 61 Eculizumab 61 CML CP